The L. helveticus strain LH KS 300 (CNCM I-3360) is used for its ability to adhere to cervix HeLa and/or Caco-2 epithelial cells, its ability to inhibit urogenital and/or gastrointestinal pathogens adhesion and growth on said epithelial cells, its ability to kill urogenital and/or gastrointestinal pathogens and its ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within said epithelial cells and also further selected for its ability to modulate the immune response of modulate the immuno competent cells, e.g. at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome. Pharmaceutical preparations containing said lactic acid bacteria strain useful for establishing, maintaining or restoring a balanced and healthy urogenital flora in females throughout life and corresponding methods of therapeutic or prophylactic treatment using them.